OPERATING PROGRAMME |
|||
Grants |
|||
| Astra Zeneca | € 30,000 | 11% | |
| Boehringer Ingelheim | € 30,000 | 11% | |
| Chiesi | € 30,000 | 11% | |
| GSK | € 30,000 | 11% | |
| Novartis | € 30,000 | 11% | |
| Pfizer | € 30,000 | 11% | |
| Regeneron | € 30,000 | 11% | |
| Sanofi Genzyme* | - | ||
| SigAirHandling | € 30,000 | 11% | |
| Stallergenes | € 30,000 | 11% | |
Membership fees |
€ 14,500 | ||
EFA PROJECT PROGRAMME |
|||
Severly, ASTHMA! |
|||
| Chiesi | € 10,000 | 1% | |
| GSK | € 10,000 | 1% | |
| Novartis | € 10,000 | 1% | |
| Regeneron | € 12,000 | 2% | |
| Sanofi Genzyme | € 12,000 | 2% | |
Capacity Building** |
|||
| Boehringer ingelheim | € 30,000 | 4% | |
| Novartis | € 30,500 | 4% | |
European Parliament Interest Group on Allergy and Asthma |
|||
| Novartis | € 11,667 | 2% | |
| Stallergenes | € 11,667 | 2% | |
European Atopic Eczema Awareness Day |
|||
| Regeneron | € 65,000 | 9% | |
| Sanofi Genzyme | € 65,000 | 9% | |
Active Patients Access Care survey*** |
|||
| Chiesi | € 38,878 | 6% | |
| GSK | € 37,878 | 5% | |
| AstraZeneca | € 77,956 | 11% | |
*Sanofi Genzyme partnership ended November 2018 and is been renewed
**4,500 EUR from Capacity Building (Novartis) moved to 2019 to cover Meet&Greet expenses
***88,488 EUR from Access Survey moved to 2019 to cover project activities